Trust Co. of Vermont Sells 671 Shares of Solventum Corporation $SOLV

Trust Co. of Vermont trimmed its position in shares of Solventum Corporation (NYSE:SOLV) by 27.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,806 shares of the company’s stock after selling 671 shares during the quarter. Trust Co. of Vermont’s holdings in Solventum were worth $137,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in SOLV. HB Wealth Management LLC boosted its stake in shares of Solventum by 5.6% during the 2nd quarter. HB Wealth Management LLC now owns 3,463 shares of the company’s stock worth $263,000 after purchasing an additional 185 shares during the period. Janney Montgomery Scott LLC lifted its stake in Solventum by 1.2% in the second quarter. Janney Montgomery Scott LLC now owns 37,696 shares of the company’s stock worth $2,859,000 after purchasing an additional 452 shares during the last quarter. V Square Quantitative Management LLC boosted its position in shares of Solventum by 8.9% during the second quarter. V Square Quantitative Management LLC now owns 5,183 shares of the company’s stock valued at $393,000 after buying an additional 422 shares during the period. ORG Wealth Partners LLC purchased a new position in shares of Solventum during the second quarter valued at approximately $71,000. Finally, Patton Fund Management Inc. bought a new position in shares of Solventum during the second quarter valued at approximately $253,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on SOLV. Piper Sandler reissued an “overweight” rating and set a $94.00 price target (up from $87.00) on shares of Solventum in a research note on Friday, August 8th. KeyCorp initiated coverage on Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating on the stock. Argus raised shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price for the company in a research note on Tuesday, July 1st. UBS Group assumed coverage on shares of Solventum in a report on Wednesday. They issued a “neutral” rating and a $77.00 price target on the stock. Finally, Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $84.60.

Solventum Stock Performance

Shares of Solventum stock opened at $74.56 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The stock’s fifty day moving average price is $72.82 and its 200-day moving average price is $72.22. The firm has a market cap of $12.93 billion, a P/E ratio of 34.52, a P/E/G ratio of 2.97 and a beta of 0.50. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $85.92.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. The company had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.